RELV vs. IBIO, TAOX, MTNB, AEON, OBSV, NBY, NRBO, AEZS, SPRB, and GRAY
Should you be buying Reliv' International stock or one of its competitors? The main competitors of Reliv' International include iBio (IBIO), Synaptogenix (TAOX), Matinas Biopharma (MTNB), AEON Biopharma (AEON), ObsEva (OBSV), NovaBay Pharmaceuticals (NBY), NeuroBo Pharmaceuticals (NRBO), Aeterna Zentaris (AEZS), Spruce Biosciences (SPRB), and Graybug Vision (GRAY).
Reliv' International vs. Its Competitors
Reliv' International (NASDAQ:RELV) and iBio (NYSE:IBIO) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.
Reliv' International has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, iBio has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
Reliv' International has higher revenue and earnings than iBio.
iBio has a consensus target price of $5.00, suggesting a potential upside of 535.32%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Reliv' International.
iBio has a net margin of 0.00% compared to Reliv' International's net margin of -0.61%. Reliv' International's return on equity of -1.89% beat iBio's return on equity.
In the previous week, iBio had 4 more articles in the media than Reliv' International. MarketBeat recorded 4 mentions for iBio and 0 mentions for Reliv' International. iBio's average media sentiment score of 0.67 beat Reliv' International's score of 0.00 indicating that iBio is being referred to more favorably in the news media.
8.0% of Reliv' International shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 31.2% of Reliv' International shares are held by company insiders. Comparatively, 0.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
iBio beats Reliv' International on 8 of the 14 factors compared between the two stocks.
Get Reliv' International News Delivered to You Automatically
Sign up to receive the latest news and ratings for RELV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RELV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reliv' International Competitors List
Related Companies and Tools
This page (NASDAQ:RELV) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access